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impact of mean tacrolimus levels and number of days with
subtherapeutic tacrolimus levels on the incidence of aGVHD.
One-hundred eight patients received tacrolimus/ mycofe-
nolate mofetil (MMF) for aGVHD prophylaxis betweenMarch
2005 and April 2012. Median age, 8 yrs; 37F/71M, malignant
(n¼61) and nonmalignant (n¼47) disorders. Stem cell
source: 18 peripheral blood stem cell donors, 49 bone
marrow donors, and 41 unrelated cord bloods. Patients were
conditioned with myeloablative (45.4%), reduced toxicity
(28.7%), or reduced intensity (25.9%) regimens. Additionally,
30 patients received alemtuzumab (27.8%) and 54 patients
received rabbit-ATG (50%). Tacrolimus was initiated at 0.03
mg/kg/d via continuous IV infusion or 0.12mg/kg/d PO, and
dose was adjusted to maintain daily steady state concen-
tration or trough levels within 10-20 ng/mL.
The overall incidence of aGVHD was 45.4%. Age, gender,
ethnicity, non-malignant/malignant diseases, related/unre-
lated donors, HLA matching, donor source, conditioning
regimen, alemtuzumab, r-ATG, and mean tacrolimus levels
<15 ng/mL during each of 4 weeks post-AlloHCT, were
examined as potential risk factors for aGVHD. Malignant
disease was the only signiﬁcant risk factor observed (OR 5.41,
95% CI 2.31-12.67, p ¼0.0001).
Mean weekly tacrolimus levels < 15 ng/mL were not signif-
icantly associated with incidence of aGVHD (p¼0.705,
p¼0.879, p¼0.952, p¼0.524) and mean levels < 10ng/mL as
suggested by Ram et al. (BBMT, 2012) were also not signiﬁ-
cant. The number of days with subtherapeutic tacrolimus
levels (< 10 ng/mL) during the ﬁrst 4 weeks post-AlloHCT
(median ¼ 10d) revealed no signiﬁcant association between
> 10d of subtherapeutic tacrolimus levels and incidence of
aGVHD (p¼0.49). Further analysis of patients with subther-
apeutic levels > 3 days per week or > 14 days over 4 weeks
were also not signiﬁcant. Risk factor analysis for subthera-
peutic tacrolimus levels demonstrated that an increase in
serum creatinine levels by 50% during the 3rd and 4th weeks
post-AlloHCT was signiﬁcantly associated with > 10 days of
subtherapeutic tacrolimus levels (p¼0.005, p¼0.01), as doses
were lowered in response to impending renal insufﬁciency.
Our results suggest that while prophylactic tacrolimus /MMF
is effective in preventing aGVHD, maintaining levels as high
as 10-20 ng/mL may not be necessary. It may be possible to
tolerate more subtherapeutic days in the ﬁrst month post-
AlloHCT without increasing the risk of aGVHD. Further
studies are necessary to determine an appropriate lower
target range for tacrolimus to reduce incidence of aGVHD
while preventing additional immune-suppression and other
toxic effects.432
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Most studies into the epidemiology of chronic graft-versus-
host- disease (cGVHD) have focused on adult hematopoietic
stem cell transplant (HSCT) recipients. To determinewhether
the clinical factors that contribute to the development of
cGVHD in pediatric HSCT recipients differed from those
implicated in adult HSCT recipients, we undertook a cross-
sectional, single institution study of pediatric HSCT re-
cipients who were more than one year following theirmyeloablative HSCT. Pediatric recipients were transplanted
between 1998 and 2011. Thirty-one (31) recipients with
either active (14) or resolved (17) cGVHDwere identiﬁed and
compared to 47 pediatric HSCT recipients without cGVHD
[40 recipients with no history of acute GVHD (Grade II-IV)
and 7 recipients with a history of only acute GVHD]. All
clinical records were re-evaluated by a single observer and
graded for the severity of both acute and cGVHD using the
NIH Consensus Scoring Criteria. Recipients’ clinical charac-
teristics were determined. Among the variables that did not
differ signiﬁcantly between HSCT recipients with and
without cGVHD were: recipient age, donor age (of bone
marrow donors), use of TBI containing preparative regimes,
malignant versus non-malignant diseases, and female donor/
male recipient. The use of bone marrow as the HSC source,
matched related donors, and the absence of acute GVHD
were all associated with a decreased probability of cGVHD.
No signiﬁcant differences were identiﬁed between the pa-
tients who had active cGVHD and those who had resolved
cGVHD.433
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Background: Cord blood transplantation (CBT) is a proven
therapy for high-risk hematologic malignancies. However,
severe grade III-IV acute graft-versus-host disease (aGVHD)
is a signiﬁcant source of morbidity and mortality and most
commonly targets the gastrointestinal (GI) tract after CBT.
We evaluated whether plasma biomarkers predict aGVHD
severity and transplant-related mortality (TRM) after CBT.
Methods: Plasma biomarkers were measured 28 days after
unrelated donor double-unit CBT in 113 consenting patients
(median age 41 years, range 1.7-69) transplanted at a single
center between 5/2006 and 5/2012. Conditioning was
myeloablative (n ¼ 37), reduced intensity (n ¼ 47), or non-
myeloablative (n ¼ 29), and CB units were 4-6/6 HLA-
matched to the recipient. The median follow-up was 44
months (range 14-84). Batched samples blinded to trans-
plant outcomes were analyzed by ELISA for levels of sup-
pressor of tumorigenicity 2 (ST2), IL-2Ra, TNFR1, HGF, IL-8,
elaﬁn, and REG3a. Patients were grouped according to being
above or below the median biomarker value. Patients who
had aGVHD onset prior to day 28 (n¼ 7) were excluded from
aGVHD evaluation.
Results: We found signiﬁcant associations between day 28
plasma biomarkers and grade II-IV aGVHD and/or 6-month
TRM (Table). IL2Ra, elaﬁn, and HGF were not signiﬁcant.
ST2 was the only biomarker associated with both day 100
aGVHD and TRM. Patients with high day 28 ST2 had signiﬁ-
cantly increased day 100 grade III-IV aGVHD of 27% (95%
CI:16-40) versus 11% (95%CI:4-20) in patients with low ST2
Table






ST2  33.9 48% (35-61) 0.045 5% (1-13) 0.001
ST2 > 33.9 64% (49-76) 23% (13-35)
TNFR1 < 4792 57% (42-69) 0.660 5% (1-13) 0.005
TNFR1 > 4792 54% (40-67) 23% (13-35)
IL8 < 51 56% (41-68) 0.652 5% (1-13) 0.005
IL8 > 51 56% (41-68) 23% (13-35)
REG3a  42 57% (42-69) 0.938 5% (1-13) 0.032
REG3a > 42 55% (40-67) 24% (13-36)
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6-month TRM, and GVHD was the most common cause of
transplant-related death. High concentrations of TNFR1, IL-8,
and REG3a were signiﬁcantly associated with 6-month TRM
and the most common cause of death in these patients was
GVHD or lung toxicity.
Conclusions: This is the ﬁrst biomarker analysis conducted
in CBT recipients. As with adult donor allografts (NEJM,
2013), high day 28 ST2 levels is associated with a subsequent
increased risk of grade II-IV and III-IV aGVHD, and 6-month
TRM. GVHD onset is after day 28 in the majority of the pa-
tients which would permit potential therapeutic interven-
tion. Thus, our ﬁndings have signiﬁcant practical
implications. Our results warrant further prospective evalu-
ation with the ultimate aim of future interventions to
ameliorate severe aGVHD and improve CBT survival.434
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Neutrophil Engraftment:
Myeloablative 93% (95%CI: 82-98)
Median 23 days (range 12-43)
Non-myeloablative 96% (95%CI: 38-99)
Median 9 days (range 7-36)
+180 Platelet Engraftment:
Myeloablative 82% (95%CI: 69-90)
Median 50 days (range 29-162)
Non-myeloablative 87% (95%CI: 62-96)
Median 34 days (range 9-59)
+100 Grade II-IV aGVHD 46% (95%CI: 35-56)
+100 Grade III-IV aGVHD 22% (95%CI: 14-31)
+180 TRM 19% (95%CI: 12-28)
1-year PFS 63% (95%CI: 51-72)Background: Calcineurin-inhibitor/MMF based prophylaxis
in DCBT is frequently associated with aGVHD. MMF dosing
in CBT has traditionally been every 12 hours (q12). We
increased MMF dosing to 1 gm every 8 hours (q8) to po-
tentially ameliorate severe aGVHD. However, the toxicity and
efﬁcacy of intensiﬁed dosing is not established.
Methods: We evaluated 173 4-6/6 HLA-matched DCBT re-
cipients (median age 39 years) transplanted for hematologic
malignancies 10/2005-5/2013. Patients received calcineurin-
inhibitor/MMF from day -3 without ATG. Before 9/2009, 83
patients (48%) received 1 gm MMF IV q12 (if 12 years 15
mg/kg/dose). From 9/2009, 90 patients (52%) received 1 gm
MMF IV q8 (15 mg/kg/dose if >12 years and <50 kg, or 20
mg/kg/dose if 12 years).
Results: The median infused CD34+ cell doses of the domi-
nant CB unit were similar in the groups. There were no dif-
ferences in the speed or success of engraftment, day 180
TRM, or 1-year PFS (Table). Day 100 grade II-IV aGVHD were
similar in the groups (46% vs 53%), and decreased day 100
grade III-IV aGVHD in the q8 group was suggested. As all
patients >50 kg received 1 gm/dose, we then analyzed the
effect of the total daily MMF dose/kg (regardless of dosing
interval) in all 173 patients. A total daily dose/kg above the
median was associated with a signiﬁcant reduction in severe
aGVHD [(23% (95%CI: 15-31) vs 10% (95%CI: 4-18), p¼0.033,
Figure].
Conclusions: Intensiﬁed q8 MMF dosing is safe from the
standpoint of engraftment, TRM and relapse. While the
reduction in severe aGVHD incidence in q8 MMF DCBT re-
cipients did not reach signiﬁcance, a total daily MMF dose/kg
above the median signiﬁcantly reduced severe aGVHD risk.MMF q8 Hour (n ¼ 90) P value
96% (95%CI: 87-99)
Median 24 days (range 12-40)
0.692
93% (95%CI: 17-99)
Median 12.5 days (range 8-46)
0.343
88% (95%CI: 77-94)
Median 45 days (range 29-137)
0.137
73% (95%CI: 40-90)
Median 34 days (range 26-77)
0.229
53% (95%CI: 42-63) 0.505
13% (95%CI: 7-21) 0.166
20% (95%CI: 13-29) 0.332
61% (95%CI: 50-70) 0.760
